A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors

Diseases and Conditions Researched

Breast - Female; Colon; Esophagus; Kidney; Liver; Lung; Melanoma, skin; Pancreas

What is the purpose of this trial?

This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors.

Participation Guidelines

Age: Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: MedImmune, Inc
Last Updated:
Study HIC#: 1403013517